Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease

Abstract

Madgula et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Drugs that act on the respiratory tract

“…While a literature review from Bournia et al (2021) [R] suggests that incidence of nintedanib-induced diarrhea among patients with systemic sclerosis-associated interstitial lung disease may be influenced by a nocebo effect in this particular patient population, this hypothesis requires further study in order to be validated. Described in more detail below, there are 5 case reports for nintedanib and 2 case reports for pirfenidone describing rare adverse reactions for these agents ( Amini et al, 2020 [A]; Arunprasath et al, 2020 [A]; Dull et al, 2020 [A]; Hasegawa et al, 2020 [A]; Imai & Tomishima, 2020 [A]; Jiménez et al, 2020 [A]; Madgula et al, 2020 [A]).…”

“…A case from the United States describes a 72-year-old man who developed a systemic fungal infection, talaromycosis, while taking nintedanib for treatment of IPF ( Madgula et al, 2020 [A]). The patient had been diagnosed with IPF 2 months prior to admission, and he was started on nintedanib therapy at that time (dose not provided).…”

Talaromycosis in a Lung Cancer Patient: A Rare Case

“…There are numerous potential reasons that could have led to this change in the epidemiology of talaromycosis, for example, improved treatment of HIV infection with highly active antiretroviral therapy and control of the HIV/AIDS epidemic, increased use of immune suppressive medications, better diagnostic tests, widened disease recognition, as well as global factors such as migration and travel increase [ 5 ]. Regardless of the cause, clinicians should be familiar with the changing epidemiology and clinical management of talaromycosis in potential hosts since an early use of antifungals is critical for improving the prognosis [ 6 - 8 ]. Herein, we report the case of an HIV-negative female patient who presented with talaromycosis coexisting with Stage IV primary non-small cell lung cancer (NSCLC).…”